QualityStocks today announces the availability of a new
audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTC: NPHC), a
biotech company specializing in the acquisition, licensing and
commercialization of pharmaceutical products and technologies for the
management of neurological disorders, cancer, autoimmune, and infectious
diseases. The interview can be heard at
http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma is developing a broad product platform for
numerous indications, and it currently has 21 patents in its intellectual
property portfolio. The QualityStocks interview begins with Deitsch describing
Nutra Pharma’s business model and three key patents: one for autoimmune
disease, one for antiviral therapeutics, and one for the treatment of pain.
Nutra Pharma also has launched a line of over-the-counter (OTC) pain drugs
(Nyloxin, for humans, and Pet Pain-Away, for dogs and cats), which financially
buoy the research and development of the company’s potential blockbuster drugs.
“The sales of these OTC drugs produce revenue that mitigates
the risk to investors and actually pays for the clinical research as we move
the products forward,” Deitsch explains.
Before highlighting other individuals on the company’s
management team, Deitsch, a seasoned biochemist, adjunct professor and author,
describes his extensive professional background, which includes 25 years
researching drugs derived from venomous animals, and employment with the
world’s largest manufacturer of dietary supplements, for which he formulated
more than 50 dietary supplements and conducted more than 50 clinical studies.
The topic then turns to several of Nutra Pharma’s historical
milestones, its strategies to increase domestic and international reach, and
how it transitioned into its current line of operations. One of Nutra Pharma’s
largest achievements to-date, says Deitsch, is obtaining Orphan Drug Status
from the U.S. FDA for RPI-78M for pediatric multiple sclerosis (MS).
“We went back and forth with the FDA for several weeks, but
it only took about five weeks from the point where we applied for Orphan Drug
Status to actually getting the Orphan Status designation, which is huge,” he
says. “It really means the FDA saw the value that we had in our drug.”
Deitsch next describes the advantages of this corporate
achievement, how it prepares the company to move into a larger market, and how
it differs from currently available drugs.
“With our drug … we stop the hyper immune response that
causes multiple sclerosis. So from the day you start taking the drug, what
we’ve seen in our clinical research is that your disease progression stops and
over time your symptoms improve. So this is a game-changer when it comes to
treating any auto-immune disease, but certainly when it comes to treating
multiple sclerosis. We really believe that we’re going to prove this in our
clinical studies and then we’ll seek a licensed partner,” he says.
In the near future, Nutra Pharma plans on commencing and
completing phase II clinical studies of RPI-78M and building a strong domestic
sales force to increase sales and availability of its Nyloxin and Pet Pain-Away
Products.
“I think that as we get this message out there we’re going
to see a huge increase in sales that of course is not only going to help bring
the company to the next level, it’s going to help us create more and more
products for our platform that we’re going to be able to license to big pharma
in the next 12-18 months,” concludes Deitsch.
For more information on the company, visit www.NutraPharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment